* Qtrly net loss attributable to common stockholders was
$13.0 million for q1 of 2016, compared to $3.3 million
The post BRIEF-Aclaris Therapeutics Q1 loss per share $0.65 appeared first on NASDAQ.
Forex – financial instrument.Forex news
* Qtrly net loss attributable to common stockholders was
$13.0 million for q1 of 2016, compared to $3.3 million
The post BRIEF-Aclaris Therapeutics Q1 loss per share $0.65 appeared first on NASDAQ.